Knockdown of Cripto-1 inhibits the proliferation, migration, invasion, and angiogenesis in prostate carcinoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cripto-1 (CR-1) is a key protein in various malignant cancers.
• The specific role of CR-1 in prostate carcinoma (PCa) is not well-defined.
• Understanding CR-1's function in PCa is essential for developing new therapeutic strategies.

Purpose of the Study:

• To investigate the role of Cripto-1 (CR-1) in prostate carcinoma (PCa).
• To determine the effects of CR-1 knockdown on PCa cell behavior, including proliferation, migration, invasion, and angiogenesis.
• To explore the underlying molecular signaling pathways affected by CR-1 expression in PCa.

Main Methods:

• CR-1 expression was downregulated using small interfering RNA (siRNA).
• Western blot was used to measure protein expression levels.
• Cell Counting Kit-8, EdU incorporation, and flow cytometry assessed proliferation and cell cycle.
• Transwell assays evaluated migration and invasion.
• Tube formation assays measured angiogenesis.
• Signaling pathway analysis included FAK/Src/PI3K and Wnt/b-catenin.

Main Results:

• CR-1 knockdown significantly inhibited PCa cell proliferation and induced G1 phase arrest, with altered expression of cell cycle regulators (p21, p27, cyclin D1, cyclin E1).
• Silencing CR-1 dramatically reduced cell migration and invasion, repressed matrix metalloproteinases, and disrupted epithelial-mesenchymal transition.
• CR-1 siRNA suppressed vascular endothelial growth factor (VEGF) secretion and reduced VEGF receptor 2 levels.
• Decreased CR-1 expression inhibited FAK/Src/PI3K and Wnt/b-catenin signaling pathways.

Conclusions:

• CR-1 plays a significant role in promoting prostate carcinoma progression.
• Downregulation of CR-1 effectively inhibits key oncogenic processes in PCa cells.
• CR-1 represents a promising therapeutic target for prostate carcinoma treatment.